Organic Active Ingredients TRIZ Cases

Novel tricyclic derivatives target MAT2A, blocking polyamine biosynthesis and cellular proliferation in MTAP-deficient cancers.

Combining a CAPRIN-1 antibody with a CDK inhibitor boosts immune-cell phagocytosis and addresses drug resistance in cancer treatment.

Controlled pH and staged solvent extraction separate impurities and produce a stable, standardized psychoactive alkaloid salt.

Systematic substituent changes create pyrazolopyrimidine inhibitors that reduce cytokine production across inflammatory diseases.

Optimized buffer ratios support stability in plastic containers while eliminating dilution before parenteral ibuprofen administration.

This case uses buffered acidic pH to limit mucus amine reactions, improving 2-DG penetration and bioavailability in mucosal delivery.

Defined solvent logP, viscosity, and boiling-point ranges improve aerosol mass while reducing terpene concentration versus propylene glycol.

Controlled crystal forms address stability and solubility limits in quinoline kinase inhibitors.

This case uses phosphate or tartrate salt formation to stabilize HDAC inhibitor compositions and simplify solid-dose manufacture.

Thienopyridinyl and thiazolopyridinyl compounds address IRAK4 selectivity, efficacy, toxicity, and stability constraints.

This case uses characteristic crystal forms to support selective JAK1/TYK2 inhibition with stability and high solubility.

This case combines an MYT1 inhibitor with chemotherapy to suppress cancer growth when RB1 function is impaired.

This combination targets fibroblast transition and proliferation to improve PF-ILD efficacy while minimizing gastrointestinal side effects.

Compound B targets FGFR, VEGFR, and CSF1R for later-line esophageal cancer treatment.

Chemically modified NRARP siRNA reaches retinal tissue through topical corneal delivery, reducing injection burden and side effects.

This case uses intestinal enzyme cleavage to release a JAK inhibitor locally, increasing gut concentration while limiting systemic exposure.

This combination targets CAPRIN-1-expressing cancer cells and enhances immune-cell phagocytosis alongside PARP inhibition.

This case combines menin-MLL and DOT1L inhibitors to suppress HOX and MEIS1 expression, induce differentiation, and reduce leukemia burden.

This case combines auxiliary lyophilization and controlled two-stage drying to reduce impurities and stabilize latamoxef sodium powder.

This case links whole-genome characterization of L. mudanjiangensis strains to cellulase development for fermentation and bioconversion.

This case uses a modular Formula I compound framework to improve FGFR selectivity and limit off-target c-kit and PDGFRa inhibition.

Ester, disulfide, or acetal groups help lipid particles protect nucleic acids, support intracellular delivery, and reduce toxicity.

Flagellin epitopes with rapamycin reduce antigen-specific memory T cells and increase regulatory T cells to limit IBD flares.

A mucoadhesive layer and dual-trigger enteric coating protect medicament through the stomach and support controlled duodenal release.

This case uses dual SYK and JAK inhibition to target BCR and cytokine signaling in relapsed or refractory B-cell malignancies.

This case uses pyridopyrimidinone derivatives to inhibit AXL kinase and counter resistance in cancer and metastasis.

Metal-complexed metformin targets mitochondria for weight reduction with fewer adverse effects.

This case uses peri-ocular transdermal lipophilic compositions to sustain ocular delivery and address eye-drop barriers.

Polymer-conjugated nucleic acids improve uptake and stability for gene silencing.

ZIF cages encapsulate active agents, while exposed ligands enable selective targeting and help limit side effects on essential organs.

This case uses nonreplicating virus-like particles in tumors or lungs to reshape immunity and suppress metastatic growth.

This case uses fragment-specific antibodies to inhibit osteopontin cleavage and integrin binding in inflammation, fibrosis, and cancer.

Modified polynucleotides improve serum stability while targeting immune activation.

This case combines biotin, zinc, vitamin C, grape seed extract, and probiotics to support treatment across multiple skin conditions.

This case examines CD2 and W-group modifications that improve Aurora-A potency and in vivo tumor growth inhibition.

This case examines botanical or synthetic THCV to reduce dyskinetic severity while preserving levodopa treatment benefits.

This case uses histidine to raise trans-urocanic acid, restore skin pH, and reduce water loss in inflammatory skin disease.

Formula (I) bicyclic compounds inhibit RIP-1 kinase, suppress necroptosis, and reduce body temperature in a TNF-driven model.

This case uses structure-guided small molecules to disrupt FKBP52–AR interactions and inhibit AR, GR, and PR activity.

Genetic testing identifies FGFR2 mutations and fusions before selective inhibitor treatment for cholangiocarcinoma.

A predetermined-distance plunger, sealed cartridge, and locking features support precise, tamper-proof, single-use dosing in emergencies.

Divinyl sulfone functionalizes polymers for crosslinking and biological interaction.

A buffered, EDTA-free phentolamine formulation maintains aqueous stability and minimizes burning or stinging in eye drops.

This case uses a high-molecular-weight PEO matrix for a crush-resistant ketamine tablet with sustained release and reduced dissociation.

This case shows how Compound I is given before, during, or after nephrotoxin exposure to reduce kidney damage.

Specific BHCl-to-phytase ratios raise metabolizable energy while cutting conventional nutrient components by 4–10% without harming growth.

This case combines anti-LY75 antibodies with Rituximab or Ibrutinib to improve lymphoma treatment and address resistance and toxicity.

This case combines melanin polymer, ceramics, and fibers to reduce armor weight while preserving ballistic protection.

This case combines sieving, ratio optimization, and silica embedding to limit coating agglomeration and preserve dissolution stability.

A PROTAC amorphous solid dispersion with surfactant and hydrophilic polymer improves bioavailability and stabilizes absorption.

Intermittent resolvin administration maintains systemic exposure while reducing metabolic degradation and patient burden.

Polysaccharides from Hirsutella sinensis mycelium lower body weight and fat pad mass, offering a non-toxic alternative to calorie restriction.

Para-L-tyrosine reverses insulin and erythropoietin resistance by displacing inhibitory tyrosine isomers from receptor binding sites.

Nano-scale micropores in a styrene-divinylbenzene copolymer resolve low selectivity by separating cannabinoids and removing pesticide residues.

Pentosan polysulfate nasal spray binds spike proteins to block viral entry, addressing reduced vaccine efficacy against variants.

Alcohol-modified microemulsions bypass first-pass liver metabolism to deliver nonderivatized hormones directly into the bloodstream.

Formula I mercaptopyrimidine compounds inhibit DNA Ligase IV enzyme activity through targeted structural modifications.

Localizing zinc-alpha2-glycoprotein to oesophageal beta3-adrenergic receptors improves insulin responsiveness while eliminating systemic side effects.

A segmented preparation process for GPR119 agonists achieves high chemical purity and enantiomeric excess through controlled sequential reactions.

Esterifying phytic acid reduces negative charge for cellular uptake, then hydrolyzes intracellularly to restore antitumor activity without toxicity.

Segmented compounds target overexpressed receptors on pathogenic immune cells, reducing toxicity to normal tissue while maintaining treatment efficacy.

Combination therapy of rivaroxaban and aspirin reduces myocardial infarction risk while avoiding unacceptable bleeding rates associated with warfarin.

Administering Compound 1 avoids nintedanib co-treatment to reduce adverse events in idiopathic pulmonary fibrosis.

An indoleamine 2-3 dioxygenase inhibitor treats obesity by modulating tryptophan metabolism to reduce inflammation and side effects.

CCL2 antagonist therapy targets the CCL2-CCR2 axis to decrease urinary albumin and repair kidney function while preventing renal disease progression.

Pivaloyl protection prevents side reactions during acylation, eliminating excess reagents and wastewater while achieving 95% yield.

Combining Factor XII and C1 inhibitors reduces thrombosis incidence while lowering required drug dosages.

Macrocyclic SIK inhibitors enhance interleukin 10 production to address unpredictable inflammatory bowel disease outcomes.

Cationic peptides regulate sepsis and inflammatory responses by down-regulating pro-inflammatory cytokines while enhancing innate immunity.

Combining Plk1 inhibitors with gemcitabine reverses resistance mechanisms in pancreatic cancer cell lines.

Administering selective CDK4/6 inhibitors at low doses reduces traumatic brain injury symptoms.

Non-ionic amphiphilic lipids prevent electrolyte-induced phase separation in adenosine phosphate emulsions, maintaining viscosity under thermal stress.

Specific inhibitors target the neprilysin active site without affecting ACE, resolving off-target enzyme interactions.

Replacing regular sugar with human milk oligosaccharides reduces health risks while preserving the desired texture and taste of soft chewy confections.

Heterocyclic amide derivatives inhibit protein kinases through targeted structural modifications.

Xanthone derivatives eliminate persistent hepatitis B viral reservoirs, resolving chronic infection limits of existing therapies.

Adenovirus and MVA vectors encode mosaic antigens to elicit immune responses maintaining viral suppression after antiretroviral therapy interruption.

Programmed RNA sequences hybridize to transcripts and recruit cellular ADAR enzymes, enabling targeted editing without exogenous protein delivery risks.

Selective CDK2 inhibitors overcome triple-negative breast cancer resistance caused by retinoblastoma protein loss.

Phospholipid nanoparticle encapsulations increase NSAID bioavailability through enhanced permeation across hydrophobic mucosa.

Pyrimidine-based sGC stimulators penetrate the blood-brain barrier to activate soluble guanylate cyclase and increase brain cGMP levels.

Formula I compounds inhibit SHP2 enzymatic activity, resolving the lack of effective therapeutic options for diseases like leukemia.

Reverse transcriptase inhibitors address Alzheimer's disease progression by inhibiting amyloid beta accumulation and protecting microglial cells from death.

Gene pair comparisons calculate raw scores to classify pancreatic tumors, resolving inconsistent molecular subtyping across diverse sample types and platforms.

Phosphorothioate and 2'O-methyl modifications enable anti-TNF oligonucleotides to reduce inflammation while minimizing side effects.

Chemically coordinating iron with plant-derived protoporphyrin yields high-purity heme iron suitable for halal supplements.

Aminoalkoxy arylsulfonamide compounds address insufficient receptor affinity and penetration issues in central nervous system disorder treatments.

Manganese porphyrin compounds modulate brain redox states to treat neurodegenerative disorders.

ATR inhibitors trigger apoptosis in ARID1A mutant cancer cells by inducing genomic instability and premature mitotic entry.

A guanidine compound reagent prolongs blood coagulation time while enhancing optical turbidity changes for sensitive detection.

Histidine buffering and polysorbate 80 prevent surface adsorption and potency loss in adeno-associated virus formulations.

Targeting miR-487b with specific antagonists reduces cell damage and improves viability during acute ischemia-reperfusion events.

Specific heterocyclic structures resolve poor inhibitor specificity and potency to treat cystic fibrosis.

A phospholipid ester conjugated with linoleic acid activates PPAR alpha to enhance anti-inflammatory responses in the central nervous system.

Amino protection enables selective triazole formation, reducing steps from nine to four while eliminating heavy metal reagents.